MAPT and amyloidosis: Validated biomarkers for ADNC used in clinical and research settings in high-income countries include characteristic magnetic resonance imaging (MRI) findings, amyloid-PET and tau-PET scanning, and CSF-biomarkers for amyloid β1–40, amyloid β1–42, phosphorylated-tau 181 and total tau15.